Exploring endocrine FGFs - structures, functions and biomedical applications

Phan, Phuc

doi:10.62347/palk2137

Int J Biochem Mol Biol

2024

DOI: 10.62347/palk2137

|View full text |Cite

Exploring endocrine FGFs - structures, functions and biomedical applications

Phuc Phan

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 223 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

New insights into FGF21 alleviates diabetic cardiomyopathy by suppressing ferroptosis: a commentary

Chen,

Wang

2024

Cardiovasc Diabetol

View full text Add to dashboard Cite

Diabetic cardiomyopathy (DCM) is a severe cardiovascular complication of diabetes characterized by myocardial hypertrophy, fibrosis, and impaired cardiac function. Fibroblast growth factor 21 (FGF21) has emerged as a promising therapeutic target due to its antifibrotic, antioxidant, and anti-inflammatory properties. Our commentary summarizes and affirms the recent study by Wang et al., which demonstrates the significant role of ferroptosis in DCM pathogenesis. FGF21 has shown promise as a therapeutic target for DCM, potentially inhibiting ferroptosis, mitigating oxidative damage, and protecting cardiomyocyte function. Mechanistically, the study identified ATF4 as an upstream regulator of FGF21 in DCM, revealing that FGF21 directly interacts with ferritin and extends its half-life, thus inhibiting ferroptosis in DCM. These findings provide a theoretical basis for understanding the pathogenesis and treatment of DCM. Our commentary suggests that future studies should explore the role of non-cardiomyocyte cell types in DCM, verify findings with clinical samples, and address comprehensive methods for ferroptosis detection. Additionally, we discuss the clinical application and future potential of FGF21-based therapies for DCM. Such efforts may contribute to advancing DCM diagnosis and treatment, fostering the development of innovative therapeutic strategies.

show abstract

New insights into FGF21 alleviates diabetic cardiomyopathy by suppressing ferroptosis: a commentary

Chen,

Wang

2024

Cardiovasc Diabetol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Exploring endocrine FGFs - structures, functions and biomedical applications

Cited by 1 publication

References 223 publications

New insights into FGF21 alleviates diabetic cardiomyopathy by suppressing ferroptosis: a commentary

New insights into FGF21 alleviates diabetic cardiomyopathy by suppressing ferroptosis: a commentary

Contact Info

Product

Resources

About